• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Public Health Advisory: Cipro for Anthrax Exposure

Audience: Health professionals and general public

FDA reminds all health professionals and the general public that Cipro is approved for the inhaled form of anthrax after an individual has been exposed. Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established, except for use in inhalational anthrax (post-exposure). The FDA Center for Drug Evaluation and Research has posted a comprehensive web page on the use of Cipro for inhalational anthrax.

[Oct 19, 2001 - Message to Health Professionals - FDA]
[Oct 19, 2001 - Information for Consumers: Questions and Answers - FDA]
[Oct 19, 2001 - Comprehensive Cipro Information Page- FDA/CDER]